venBio Global Strategic — 2025 Investments
3 investments dated 2025 · listed companies and verified rows first · show all
Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing selective small molecule inhibitors to treat rare genetic and age-related diseases caused by dysregulated cellular metabolism.
BiotechBerkeley, US
Allison J. Hulme(CEO & President)John Kincaid(Chief Scientific Officer)Davis Ryman(Executive Officer)Micah Zajic(Executive Officer)Ian Massey(Executive Officer)Stelios Tzannis(Executive Officer, Director)
Board seatRichard Gaster· per SEC Form D · $50.4M raise · filed May 2024
Co-investorsCoastCapCTI Life Sciences Fund L.P.FJ LabsSofinnova VenturesvenBio Partners
Arpeggio Bio develops pharmaceutical drugs that target transcription factors using artificial intelligence and RNA-sequencing technology, with lead programs in development for melanoma treatment and rare disease applications.
BiotechHealthtechBoulder, US
Joey Azofeifa(Founder)inJoseph G. Azofeifa(Executive Officer, Director)Laura Norris(Executive Officer, Director)Timothy Read(Executive Officer, Director)Eric Martin(Executive Officer)
BoardAmit Mehta(Director)
Board seatAaron Royston· per SEC Form D · $35.3M raise · filed Nov 2025
Co-investorsFifty YearsFundersClubTau VenturesvenBio PartnersY CombinatorBoxOne Ventures+1 more
Eyconis is a clinical-stage biotechnology company developing long-acting ophthalmic therapies for serious eye diseases such as wet age-related macular degeneration and diabetic macular edema using the TransCon technology platform.
BiotechDigital HealthMedical DevicesRedwood City, US
Emmett Cunningham(Executive Officer, Director)Mark Bachleda(Executive Officer, Director)inRobert Vitti(Executive Officer)Oliver Stauch(Executive Officer)inOliver Boris Stauch(Executive Officer)Conrad Wang(Director)
Board seatYvonne Yamanaka· per SEC Form D · $89.8M raise · filed Oct 2025
Co-investorsFrazier Life SciencesHealthQuest CapitalvenBio Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.